Wed 11/30/2022 05:09 AM
Share this article:
Global oncology services provider GenesisCare has been hitting the headlines this year for all the wrong reasons. Most recently, it was reported that the group’s net leverage reached 40x at the end of September. GenesisCare’s struggles have come about despite shareholder support, on the back of its ill-fated acquisition of U.S.-based 21st Century Oncology.

Against the backdrop of a potential restructuring, investors have also been concerned about an “Envision” style new money transaction...
Share this article:
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2024 Reorg Research, Inc. All rights reserved.
Thank you for signing up
for Reorg on the Record!